This interview discusses how BCMA-directed CAR T-cell therapy in multiple myeloma may be more effective when administered ...

While the use of radiation bridging therapy (BT) in chimeric antigen receptor (CAR) T-cell therapy for blood cancer is expanding, plenty of unanswered questions remain on topics such as ideal timing ...

FDA approval criteria primarily dictate the sequencing of multiple myeloma therapies, often restricting bispecific antibodies to later treatment lines. Institutional practices vary in using CAR T-cell ...

CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

CAR T-cell therapy has revolutionized treatment for many blood cancers. However, the benefits of its use in the early stages of care remain uncertain. Chimeric antigen receptor (CAR) T-cell therapy ...

Colleen Mabasa, a patient with multiple myeloma, discusses her CAR T-cell therapy journey and the pivotal role self-advocacy ...

A study published in the Journal of Clinical Oncology confirms that one of the first Food and Drug Administration-approved CAR-T cell therapies offers long-term survival and potential cures for adult ...

Improved QOL is observed in patients over two years post-infusion and those without disease progression, highlighting the ...

A personal reflection on the promise and limits of CAR T therapy—its breakthroughs, failures, scientific bottlenecks, and what must change to truly save more lives.